• Aliskiren + Hydrochlorothiazide is indicated for the treatment of hypertension (high blood pressure) in patients who require combination therapy.
• It may be used as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals.Initial dose: 150 mg-12.5 mg or 150 mg-25 mg once daily
  
  Maximum dose: Aliskiren-hydrochlorothiazide 300/25 mg orally daily

• The usual adult dosage for aliskiren + hydrochlorothiazide is  150 mg-12.5 mg or 150 mg-25 mg once daily
• Maximum dose: Aliskiren + hydrochlorothiazide 300/25 mg orally daily

Adverse reactions associated with Aliskiren + Hydrochlorothiazide include-

• Hypotension (low blood pressure)
• Hyperkalemia (high potassium levels)
• Dizziness
• Headache
• Fatigue
• Diarrhea
• Cough
• Nausea
• Abdominal pain
• Nasopharyngitis (inflammation of the nose and throat)

Hypotension (Low Blood Pressure)

Hyperkalemia (High Potassium)

Dizziness

Coughing

• Hypotension: Aliskiren + Hydrochlorothiazide can cause symptomatic hypotension, particularly in patients with volume depletion.
• Hyperkalemia: Monitoring of potassium levels is recommended, especially in patients with renal impairment or diabetes.
• Renal impairment: Aliskiren + Hydrochlorothiazide is not recommended in patients with severe renal impairment or on dialysis.
• Fetal toxicity: Aliskiren can cause fetal harm when administered to pregnant women. It should be discontinued as soon as pregnancy is detected.
• Electrolyte abnormalities: Regular monitoring of electrolytes, including sodium, potassium, and magnesium, is advised.